Covid, FDA and vaccine
Digest more
The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.
The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under age 65, effectively limiting them to older adults and those at risk of developing severe illness.
In India, the most prominent symbol of the Covid response was the Serum Institute of India. The company became the world’s largest Covid vaccine supplier (Covishield), propelling it, and CEO Adar Poonawalla, to record revenues and global recognition.
A rehab firm will pay a cash settlement to an occupational therapist it fired when the worker declined a COVID-19 vaccination.
Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.
Explore more
Agency leaders said there was evidence to justify approval only for older people and those with medical conditions. Many others may not be able to get the shots.